Deciphera Pharmaceuticals Increases Size of Series B Financing to
over $90 Million with Addition of SV Life Sciences

WALTHAM, Mass.--(EON: Enhanced Online News)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company
focused on developing advanced kinase inhibitor treatments, today
announced that it has increased the size of its Series B financing to
over $90 million with the addition of SV Life Sciences. In September
2015, the Company announced the initial closing of the Series B, which
was led by New Leaf Venture Partners and joined by Deciphera’s existing
investors, to fund development of the Company’s pipeline of proprietary
switch control kinase inhibitors. Concurrent with the financing, Michael
Ross Ph.D., Managing Partner at SV Life Sciences, will join Deciphera’s
board of directors.

“The Company is very pleased to welcome SV Life Sciences, a premiere
healthcare investor, to the Deciphera team”

"The Company is very pleased to welcome SV Life Sciences, a premiere
healthcare investor, to the Deciphera team," said Michael D. Taylor,
Ph.D., President and CEO of Deciphera Pharmaceuticals. "SV Life
Sciences' investment in our upsized Series B financing further
highlights the breadth and depth of Deciphera’s clinical pipeline of
oncology candidates and the differentiated nature of our technology
platform. We look forward to the valuable contributions that Mike Ross
and the SV team will bring to Deciphera as we advance our pipeline of
unique switch control kinase inhibitors designed to improve the rate and
durability of responses in targeted therapies for cancer.”

SV Life Sciences’ investment will contribute to rapid progression of
Deciphera’s lead tumor-targeting clinical programs, including
Altiratinib and DCC-2618, as well as its immuno-targeted therapies such
as DCC-3014 and Rebastanib, offering the potential to provide patients
with innovative new therapeutic options while building a strong
oncology-focused biotechnology company.

Deciphera’s proprietary switch control kinase inhibitor technology
platform has enabled the development of tumor-targeted and
immuno-targeted kinase inhibitor therapeutics that provide robust and
durable kinase binding and block key cancer signaling mechanisms and
mutational resistance. Deciphera’s product pipeline includes four
product candidates in Phase 1 clinical development including
altiratinib, a MET/TRK inhibitor currently in a late Phase 1 dose
escalation study with Phase 1 expansion trials in patients with
actionable MET and TRK genomic alterations expected to start early in
2016; DCC-2618, a pan-KIT inhibitor currently in a Phase 1 dose
escalation trial; rebastinib, a TIE2 kinase inhibitor; and a pan-RAF
inhibitor (LY-3009120) being developed by partner Eli Lilly. In
addition, DCC-3014, Deciphera’s selective small molecule inhibitor of
CSF1R, is currently in preclinical development and expected to enter
first-in-human studies in 2016.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals seeks to improve treatment for patients with
cancer by designing kinase inhibitor therapies that target the hallmarks
of cancer biology. We specifically design our small molecule compounds
to simultaneously block multiple cancer signaling mechanisms in the
tumor cell and the tumor microenvironment to prevent growth and spread.
Deciphera’s unique approach represents an important advance over current
therapies in the durability of kinase inhibition and resiliency to
genetic mutations to provide greater benefit across a range of cancers.
Deciphera’s business strategy is to advance its drug candidates for
genetically defined cancers and cancers that target the tumor
microenvironment through both proprietary and partnered programs.

About SV Life Sciences

SV Life Sciences is a leading international life sciences venture
capital firm. SVLS affiliated funds have been investing in life sciences
companies since the early 1980s and the firm closed its first dedicated
life sciences fund in 1994.

The SVLS team manages five private venture capital funds with
approximately $1.9 billion of capital under management. The firm employs
a diversified strategy within life sciences in order to selectively
capitalize on an expanding opportunity in biotech, medical devices and
health-care services. SVLS has offices in Boston, London and San
Francisco. For more information please visit http://www.svlsa.com/index.html.

WALTHAM, Mass.--(EON: Enhanced Online News)--"We are very pleased that the ongoing Phase 1 trial of DCC-2618 continues to be well-tolerated and demonstrates encouraging disease control," said Micha... more »